How do cancer and cancer treatments affect the reproductive function of men? Can this affect the health of their direct descendants and subsequent generations? To get a clear picture, INRS researchers evaluate the current state of knowledge on this public health issue in a review article appearing in the journal Gynécologie Obstétrique & Fertilité. They analyze the results of scientific studies to find evidence and better understand the mechanisms of action of chemotherapy on spermatogenesis. The initial observation is that cancer survivors have greater difficulty becoming fathers and use more assisted reproductive techniques, regardless of their age at diagnosis.
Despite a lower birth rate, it seems that having had cancer has no significant affects on the health of their children. However, there is no epidemiological study on the transgenerational effects of cancer treatments. There is also no data available on the reproductive function of the descendants of cancer survivors; hence the importance of continuing cohort studies over multiple generations.
“It’s important to understand the mechanisms of action of chemotherapy on spermatogenesis to help clinicians make informed decisions on adjusting treatment, reducing side effects, and better advising patients on family planning.”Géraldine Delbès, reproductive toxicology specialist and the author in charge of this study.
Published in Gynécologie Obstétrique & Fertilité, this research received a grant from the Cole Foundation and master’s scholarships from the Canadian Institutes of Health Research and Fonds de recherche du Québec – Santé. The results are presented in the article “Transgenerational impact of chemotherapy: Would the father exposure impact the health of future progeny?” produced by researchers A. Tremblay, H. Beaud, and Dr. Géraldine Delbès of INRS. DOI: 10.1016.jgofs.2017.09.004